Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Stable COPD: inhalers, rehabilitation and oxygen

Respiratory · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

Stable-treatment escalation is not appropriate for sudden or marked deterioration. New resting hypoxaemia, confusion, cyanosis, haemoptysis, chest pain, unilateral signs or oedema with acute breathlessness requires urgent assessment for exacerbation, pneumonia, pneumothorax, pulmonary embolism or cardiac disease.

Synopsis

Build a benefit-led stable COPD plan using smoking treatment, rehabilitation, device-matched bronchodilation, selective corticosteroid/advanced therapy and formal oxygen assessment.

  • Treat tobacco dependence, physical deconditioning, vaccination needs, nutrition and comorbidity alongside inhalers; medication alone is not comprehensive COPD care.
  • Use a short-acting bronchodilator when needed initially. If breathlessness or exacerbations persist without asthmatic/steroid-responsive features, offer LABA+LAMA.
  • If asthmatic features suggest steroid responsiveness, consider LABA+ICS; review pneumonia and systemic ICS risk and never use ICS monotherapy for COPD.
  • For persistent disabling symptoms or exacerbations on dual therapy, consider triple LABA+LAMA+ICS according to phenotype and trial response; review and revert if a symptom-led trial gives no benefit.
  • Choose one device the patient can and will use, demonstrate technique, minimise duplicate drug classes and prescribe the exact brand/dose.
  • Offer pulmonary rehabilitation to functionally limited people, generally MRC dyspnoea grade 3 or more, and after recent hospitalisation when appropriate.
  • Consider mucolytic therapy for chronic productive cough and continue only if symptoms improve; do not use cough suppressants routinely in stable COPD.
  • LTOT is for confirmed stable hypoxaemia after specialist ABG assessment: PaO2 at or below 7.3 kPa, or 7.3-8.0 kPa with polycythaemia, peripheral oedema or pulmonary hypertension.
  • LTOT benefit requires at least 15 hours/day. It is not prescribed simply for breathlessness with normal oxygenation, and smoking/fire risk must be assessed.
  • Since March 2026, NICE allows specialist add-on dupilumab for uncontrolled COPD with eosinophils at least 0.3 x10^9/L despite triple therapy, or LABA+LAMA when ICS is inappropriate; assess response at 12 months.

    • Key red flags

    Chronic hypoxaemia

    Stable SpO2 at or below 92%, cyanosis, polycythaemia, pulmonary hypertension, peripheral oedema or very severe obstruction should prompt formal ABG-based LTOT assessment, not an oxygen prescription from oximetry alone.

    Investigation priorities

    01
    Symptom, MRC and exacerbation reviewFirst step

    Choose treatment target and measure benefit.

    Management branches

    InhalersNICE stable inhaler sequence

    Persistent breathlessness or exacerbations after short-acting therapy and non-pharmacological care.

    1. Check diagnosis, smoking treatment, technique/adherence and offer pulmonary rehabilitation. Keep SABA or SAMA as-needed initially; stop regular SAMA when a LAMA begins.
    2. Without asthmatic/steroid-responsive features, offer LABA+LAMA. With such features, consider LABA+ICS, explaining ICS benefits and pneumonia risk.
    3. If on LABA+LAMA with quality-of-life-limiting daily symptoms, consider a 3-month triple-therapy trial and revert if no improvement. If severe or 2 moderate exacerbations/year occur, offer triple therapy.
    4. If on LABA+ICS with persistent symptoms or exacerbations, offer LAMA to make triple therapy. Reconcile drugs/device and review response/harms after every change.
    OxygenFormal LTOT pathway

    Stable SpO2 ≤92%, very severe obstruction, cyanosis, polycythaemia, oedema or pulmonary hypertension.

    1. Optimise COPD treatment and assess when stable. Obtain ABGs on 2 occasions at least 3 weeks apart through a specialist oxygen service.

    Key medicines

    Tiotropium/olodaterol LABA+LAMA (example)5 micrograms tiotropium plus 5 micrograms olodaterol inhaled once daily as 2 puffs of Respimat 2.5/2.5 micrograms.Not a reliever. Check renal function/antimuscarinic effects, glaucoma/urinary retention, tachyarrhythmia and device technique; avoid duplicate LABA/LAMA.
    Beclometasone/formoterol/glycopyrronium triple inhaler (example)Trimbow 87/5/9 micrograms: 2 inhalations twice daily; maximum 2 inhalations twice daily.Rinse mouth; monitor pneumonia, thrush, bruising and systemic ICS effects. Confirm indication and response; this example is not interchangeable with other strengths/devices.
    Open full textbook →Answer 2 questions
    Sources and review status7 sources · checked 27 Aug 2026 · clinical review pending+
    Sources

    Sources and review status

    National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

    • NICE NG115: COPD diagnosis and managementStable inhalers, rehabilitation, oxygen and add-on principles.
    • NICE TA1142: dupilumab for uncontrolled eosinophilic COPDMarch 2026 eligibility and 12-month stopping rule.
    • NICE TA461: roflumilast for severe COPDSpecialist add-on criteria.
    • BTS pulmonary rehabilitation guidelineProgramme principles and clinical benefit.
    • BTS emergency oxygen guidelineControlled oxygen and hypercapnia risk.
    • Spiolto Respimat SmPCExample LABA+LAMA product dose.
    • Dupixent SmPCCOPD dose and 52-week response consideration.

    Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

    Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
    Offer LTOT for PaO2 ≤7.3 kPa, or 7.3-8.0 kPa with secondary polycythaemia, peripheral oedema or pulmonary hypertension. Prescribe enough for at least 15 hours/day and titrate to the service target.
  • Complete smoking/vaping and household fire-risk assessment, provide equipment education and review at least annually with oximetry and adherence. Refer hypercapnic/acidotic patients for long-term NIV consideration.